Markets:

Overview

News

Currencies

International

Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

253.82 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

May 08, 2025

From Natera, Inc.

Via Business Wire

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Preview: Natera's Earnings ↗

May 07, 2025

Via Benzinga

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

May 07, 2025

From Natera, Inc.

Via Business Wire

Peering Into Natera's Recent Short Interest ↗

May 02, 2025

Via Benzinga

How Do Investors Really Feel About Natera? ↗

March 11, 2025

Via Benzinga

What To Expect From Natera’s (NTRA) Q1 Earnings

May 07, 2025

Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings tomorrow after market hours. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

May 05, 2025

From Natera, Inc.

Via Business Wire

Natera to Report its First Quarter Results on May 8, 2025

May 01, 2025

From Natera, Inc.

Via Business Wire

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

April 29, 2025

From Natera, Inc.

Via Business Wire

2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

April 29, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗

April 28, 2025

Via Benzinga

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

April 24, 2025

From Natera, Inc.

Via Business Wire

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

April 22, 2025

From Natera, Inc.

Via Business Wire

1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 to Turn Down

April 18, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today ↗

April 17, 2025

Via Benzinga

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. ↗

April 17, 2025

A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Via Investor's Business Daily

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

April 15, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

April 14, 2025

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

Via StockStory

Topics Artificial Intelligence

Assessing Natera: Insights From 10 Financial Analysts ↗

April 10, 2025

Via Benzinga

3 Reasons NTRA Has Explosive Upside Potential

April 08, 2025

Natera currently trades at $141.03 and has been a dream stock for shareholders. It’s returned 351% since April 2020, blowing past the S&P 500’s 87.1% gain. The company has also beaten the index over...

Via StockStory

Topics Government Stocks

27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks ↗

April 07, 2025

Via The Motley Fool

Topics Artificial Intelligence

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

April 07, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst...

Via StockStory

Topics Artificial Intelligence

Is the Market Bullish or Bearish on Natera? ↗

April 04, 2025

Via Benzinga

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

March 25, 2025

From Natera, Inc.

Via Business Wire

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

March 20, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.

Via StockStory

Topics Artificial Intelligence

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings ↗

March 19, 2025

Via The Motley Fool

1 Mid-Cap Stock to Own for Decades and 2 to Brush Off

March 18, 2025

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

Why Is Natera (NTRA) Stock Soaring Today

March 11, 2025

Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 5.2% in the afternoon session after stocks rebounded, following a broad-based sell-off the previous day. The Nasdaq was down 4%, while the...

Via StockStory

Topics Stocks World Trade

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

March 10, 2025

From Natera, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.